Clinical Director of Imperial College’s Center for Psychedelic Research Joins Entheon Advisory Board
Vancouver, British Columbia–(Newsfile Corp. – August 25, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (” Entheon ” or the ” Company “), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that Dr. David Erritzoe, the current Clinical Director of the Imperial College’s Center for Psychedelic Research, has been […]
HAVN Life Signs Agreement to Supply Psilocybin for Mycotopia Therapies
VANCOUVER, BC / ACCESSWIRE / August 25, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the “Company” or “Havn Life”) a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs that support brain health and enhance the capabilities of the mind, recently signed an agreement to supply naturally-derived psilocybin to Mycotopia […]
Clinical Director of Imperial College’s Center for Psychedelic Research Joins Entheon Advisory Board
Vancouver, British Columbia–(Newsfile Corp. – August 25, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (” Entheon ” or the ” Company “), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that Dr. David Erritzoe, the current Clinical Director of the Imperial College’s Center for Psychedelic Research, has been […]
Silo Pharma Advances Psychedelic Patent Portfolio
Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced the filing of three distinct Patent Cooperation Treaty (PCT) patent applications pertaining to the central nervous system delivery of unique anti-inflammatory therapeutics coupled with psilocybin. “Each of these PCT applications relates to the continued research […]
Tryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of Florida
San Diego, California–(Newsfile Corp. – August 24, 2021) – Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company”), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today it has completed the training of psychotherapists for its upcoming Phase 2a clinical trial using synthetic psilocybin in combination with psychotherapy for […]
Entheon Biomedical Corp. Announces DTC Eligibility
Vancouver, British Columbia–(Newsfile Corp. – August 24, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (” Entheon ” or the ” Company “), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that its common shares are now eligible for electronic clearing and settlement through the Depository Trust Company (“DTC”) […]
MindMed Announces Collaboration With Forian To Advance Development Of Personalized Psychiatry For Anxiety Disorders
NEW YORK , Aug. 24, 2021 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading biotech company developing psychedelic-inspired therapies, has agreed to work with Forian Inc. (NASDAQ: FORA), a leading provider of evidence-based support for more comprehensive clinical and commercial decision-making. MindMed and Forian will collaborate to develop best practices […]
Mydecine Innovations Group Announces Mailing of Management Information Circular and Provides Update on Spin-Out of U.S. Cannabis Assets
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company”), is pleased to announce that it has filed and mailed its management information circular (the “Information Circular”) and related meeting and proxy materials for the annual general and special meeting of the shareholders of the Company to be held virtually on Monday, September […]
